Characteristics of S100B and Neuron Specific Enolase in Differentiating Acute Vertigo Cases with Central Cause; a Diagnostic Accuracy Study
Archives of Academic Emergency Medicine,
Vol. 8 No. 1 (2020),
7 January 2020
Introduction: Differentiating central vertigo from peripheral ones poses a challenge to specialists. The present study aimed to examine the potential screening value of S100B and neuron-specific enolase (NSE) in this regard.
Methods: This prospective cross-sectional study recruited adult acute vertigo patients with suspected central causes visiting the emergency department (ED) in the first six hours since the onset of symptoms. The screening performance characteristics of S100B and NSE biomarkers in differentiating central vertigo cases were measured considering brain magnetic resonance imaging (MRI) as the reference test.
Results: 85 cases who met the criteria were enrolled to the study (82.3% female). The MRI of 21 (24.7%) cases had abnormal findings. The two groups were the same in terms of age, sex, and vital signs. Patients with abnormal brain MRI had significantly higher levels of S100B (p < 0.001) and NSE (p < 0.001). S100B and NSE had area under the receiver operating characteristic (ROC) curve of 90.3 (95% CI: 80.7 â€“ 99.8) and 96.9 (95% CI: 93.7 â€“ 100.0) in differentiating the central causes of acute vertigo, respectively. Â At the cut-off point of above 119.68 pg/l, S100b had sensitivity of 90.00% (95% CI: 78.83 â€“95.86) and specificity of 92.00% (95% CI: 72.49 â€“ 98.60). Â The sensitivity and specificity of NSE at the cut-off point of above 18.12 ng/ml were 100.00% (95% CI: 93.14 â€“ 100.00) and 89.47% (95% CI: 65.46 â€“ 98.15), respectively.
Conclusion: The serum levels of S100B and NSE were significantly higher in patients with central vertigo, and could therefore be considered as accurate tools in screening acute vertigo cases with central causes in ED.
- Vestibular neuronitis
- S100B protein
- phosphopyruvate hydratase
How to Cite
Wipperman J. Dizziness and Vertigo. Primary care. 2014;41(1):115-31.
Kerber KA, Meurer WJ, West BT, Fendrick AM. Dizziness presentations in U.S. emergency departments, 1995-2004. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2008;15(8):744-50.
Peng B. Cervical Vertigo: Historical Reviews and Advances. World neurosurgery. 2018;109:347-50.
Hussami A, Casulli C, Fayard C, Caillier-Minier M, Vion P, Minier D. Vertebrobasilar stroke secondary to giant-cell arteritis without biological inflammatory syndrome. Revue neurologique. 2016;172(3):250-2.
Dieterich M, Glasauer S, Brandt T. Why acute unilateral vestibular midbrain lesions rarely manifest with rotational vertigo: a clinical and modelling approach to head direction cell function. Journal of neurology. 2018;265(5):1184-98.
Schiff L, Hadker N, Weiser S, Rausch C. A literature review of the feasibility of glial fibrillary acidic protein as a biomarker for stroke and traumatic brain injury. Molecular diagnosis & therapy. 2012;16(2):79-92.
Bruzzone MG, Grisoli M, De Simone T, Regna-Gladin C. Neuroradiological features of vertigo. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2004;25 Suppl 1:S20-3.
Newman-Toker DE, Della Santina CC, Blitz AM. Vertigo and hearing loss. Handbook of clinical neurology. 2016;136:905-21.
Haque A, Ray SK, Cox A, Banik NL. Neuron specific enolase: a promising therapeutic target in acute spinal cord injury. Metabolic brain disease. 2016;31(3):487-95.
Samanci Y, Samanci B, Sahin E, Altiokka-Uzun G, Kucukali CI, Tuzun E, et al. Neuron-specific enolase levels as a marker for possible neuronal damage in idiopathic intracranial hypertension. Acta neurologica Belgica. 2017;117(3):707-11.
Liu B, Xie Z, Liu G, Gu Y, Pan S, Wang H. Elevated neuron-specific enolase and S100 calcium-binding protein B concentrations in cerebrospinal fluid of patients with anti-N-methyl-d-aspartate receptor encephalitis. Clinica chimica acta; international journal of clinical chemistry. 2018;480:79-83.
Olivecrona M, Rodling-Wahlstrom M, Naredi S, Koskinen LO. S-100B and neuron specific enolase are poor outcome predictors in severe traumatic brain injury treated by an intracranial pressure targeted therapy. Journal of neurology, neurosurgery, and psychiatry. 2009;80(11):1241-7.
Kogel D, Peters M, Konig HG, Hashemi SM, Bui NT, Arolt V, et al. S100B potently activates p65/c-Rel transcriptional complexes in hippocampal neurons: Clinical implications for the role of S100B in excitotoxic brain injury. Neuroscience. 2004;127(4):913-20.
Hajdukova L, Sobek O, Prchalova D, Bilkova Z, Koudelkova M, Lukaskova J, et al. Biomarkers of Brain Damage: S100B and NSE Concentrations in Cerebrospinal Fluid--A Normative Study. BioMed research international. 2015;2015:379071.
Kartal AG, Yilmaz S, Yaka E, Pekdemir M, Sarisoy HT, Cekmen MB, et al. Diagnostic value of S100B protein in the differential diagnosis of acute vertigo in the emergency department. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2014;21(7):736-41.
Thelin EP, Nelson DW, Bellander BM. A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury. Acta neurochirurgica. 2017;159(2):209-25.
Dijkhuizen RM. Advances in MRI-Based Detection of Cerebrovascular Changes after Experimental Traumatic Brain Injury. Translational stroke research. 2011;2(4):524-32.
Bandyopadhyay S, Hennes H, Gorelick MH, Wells RG, Walsh-Kelly CM. Serum neuron-specific enolase as a predictor of short-term outcome in children with closed traumatic brain injury. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2005;12(8):732-8.
- Abstract Viewed: 189 times
- PDF Downloaded: 130 times